Evidence map›Paper›PMID 37612324›Full record

ArticleScientific reports2023

Integration of plasma and CSF metabolomics with CSF proteomic reveals novel associations between lipid mediators and central nervous system vascular and energy metabolism.

Kamil Borkowski, Nicholas T Seyfried, Matthias Arnold, James J Lah, Allan I Levey, Chadwick M Hales, Eric B Dammer, Colette Blach, Gregory Louie, Rima Kaddurah-Daouk and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Recent Advances in Human Cerebrospinal Fluid Proteomics.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Kamil BorkowskiWest Coast Metabolomics Center, Genome Center, University of California Davis, Davis, CA, 95616, USA. kborkowski@ucdavis.edu.
Nicholas T SeyfriedDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Matthias ArnoldInstitute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, Neuherberg, Germany.
James J LahDepartment of Neurology, Emory University, Atlanta, GA, 30329, USA.
Allan I LeveyDepartment of Neurology, Emory University, Atlanta, GA, 30329, USA.
Chadwick M HalesDepartment of Neurology, Emory University, Atlanta, GA, 30329, USA.
Eric B DammerDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Colette BlachDuke Molecular Physiology Institute, Duke University, Durham, NC, 27708, USA.
Gregory LouieDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, 27708, USA.
Rima Kaddurah-DaoukDepartment of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, 27708, USA. Rima.kaddurahdaouk@duke.edu.
John W NewmanWest Coast Metabolomics Center, Genome Center, University of California Davis, Davis, CA, 95616, USA.
Emory University · USDuke University · USUniversity of California, Davis · USHelmholtz Zentrum München · DE

Funding

Project 4 - Mechanistic studies on the role of the gut microbiome in models for Alzheimer's diseaseU19AG063744 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Rima F Kaddurah-Daouk · 2019 to 2026
$54.1M
The Emory Healthy Brain Study: Discovering Predictive Biomarkers for Alzheimer's DiseaseR01AG070937 · NIA · EMORY UNIVERSITY · PI LAH, JAMES J · 2021 to 2025
$35.2M
The Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI ALLAN I LEVEY · 2020 to 2026
$29.0M
Metabolomic Signatures for Disease Sub-classification and Target Prioritization in AMP-ADU01AG061359 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KASTENMULLER, GABI · 2018 to 2022
$10.0M
Metabolic Signatures Underlying Vascular Risk Factors for Alzheimer-type DementiasRF1AG051550 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KLING, MITCHEL ALLAN · 2015 to 2016
$6.3M
Metabolic Networks and Pathways Predictive of Sex Differences in AD Risk and Responsiveness to TreatmentRF1AG059093 · NIA · DUKE UNIVERSITY · PI BRINTON, ROBERTA EILEEN, CHANG, RUI · 2018 to 2018
$5.9M
Metabolic Networks and Pathways in Alzheimer's DiseaseR01AG046171 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F · 2014 to 2017
$4.4M
TargetAD: A systems multi-omics approach to drug repositioning in Alzheimer's diseaseR01AG069901 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI Matthias Arnold, Jan Krumsiek · 2021 to 2026
$3.7M
Metabolic Network Analysis of Biochemical Trajectories in Alzheimer's DiseaseRF1AG057452 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, KASTENMULLER, GABI · 2017 to 2017
$3.5M
Gut Liver Brain Biochemical Axis in Alzheimer's DiseaseRF1AG058942 · NIA · DUKE UNIVERSITY · PI KADDURAH-DAOUK, RIMA F, VAN DUIJN, CORNELIA MARJA · 2018 to 2018
$3.4M
NIA NIH HHS P30 AG066511NIA NIH HHS R01 AG046171NIA NIH HHS R01 AG069901NIA NIH HHS R01 AG070937NIA NIH HHS RF1 AG051550NIA NIH HHS RF1 AG057452NIA NIH HHS RF1 AG058942NIA NIH HHS RF1 AG059093NIA NIH HHS U01 AG061359NIA NIH HHS U19 AG063744
6 · The paper itself

Abstract

Integration of the omics data, including metabolomics and proteomics, provides a unique opportunity to search for new associations within metabolic disorders, including Alzheimer's disease. Using metabolomics, we have previously profiled oxylipins, endocannabinoids, bile acids, and steroids in 293 CSF and 202 matched plasma samples from AD cases and healthy controls and identified both central and peripheral markers of AD pathology within inflammation-regulating cytochrome p450/soluble epoxide hydrolase pathway. Additionally, using proteomics, we have identified five cerebrospinal fluid protein panels, involved in the regulation of energy metabolism, vasculature, myelin/oligodendrocyte, glia/inflammation, and synapses/neurons, affected in AD, and reflective of AD-related changes in the brain. In the current manuscript, using metabolomics-proteomics data integration, we describe new associations between peripheral and central lipid mediators, with the above-described CSF protein panels. Particularly strong associations were observed between cytochrome p450/soluble epoxide hydrolase metabolites, bile acids, and proteins involved in glycolysis, blood coagulation, and vascular inflammation and the regulators of extracellular matrix. Those metabolic associations were not observed at the gene-co-expression level in the central nervous system. In summary, this manuscript provides new information regarding Alzheimer's disease, linking both central and peripheral metabolism, and illustrates the necessity for the "omics" data integration to uncover associations beyond gene co-expression.

Indexed as

Alzheimer DiseaseBile Acids and SaltsCentral Nervous SystemEndocannabinoidsEnergy MetabolismEpoxide HydrolasesHumansMetabolomicsProteomicsBile Acids and SaltsEndocannabinoidsEpoxide Hydrolases

Identifiers

PMID37612324
PMCPMC10447532
OpenAlexW4386098040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.